Table 3. Patient characteristics:... | American Society of Hematology

Table 3.

Patient characteristics: analysis C

	ASCT (n = 117)		No ASCT (n = 96)
	n	%	n	%
Male sex	71	61	67	70
Age at diagnosis, y
Median	54		54.5
Range	20-64		19-64
Subtype of T-cell NHL
ALK⁻ ALCL	28	24	16	17
PTCL NOS	41	35	34	35
AITL*	48	41	46	48
Ann Arbor stage
2	13	11	13	13
3-4	104	89	83	87
Elevated LDH	56	48	50	52
WHO performance score
0-2	73	63	42	45
3-4	2	1	4	4
Unknown	42	36	50	52
>1 extranodal localization	29	25	23	24
IPI score
0-2	90	77	64	67
3-5	27	23	32	33

	ASCT (n = 117)		No ASCT (n = 96)
	n	%	n	%
Male sex	71	61	67	70
Age at diagnosis, y
Median	54		54.5
Range	20-64		19-64
Subtype of T-cell NHL
ALK⁻ ALCL	28	24	16	17
PTCL NOS	41	35	34	35
AITL*	48	41	46	48
Ann Arbor stage
2	13	11	13	13
3-4	104	89	83	87
Elevated LDH	56	48	50	52
WHO performance score
0-2	73	63	42	45
3-4	2	1	4	4
Unknown	42	36	50	52
>1 extranodal localization	29	25	23	24
IPI score
0-2	90	77	64	67
3-5	27	23	32	33

Patients undergoing ASCT vs not undergoing ASCT during first-line treatment.

Including T-cell NHL, follicular helper T cells.